Four China COVID-19 Vaccines Safe in 60,000 Phase III Subjects
October 21, 2020 at 06:48 AM EDT
Four China biopharmas have dosed a total of 60,000 people in Phase III trials of their respective COVID-19 vaccines without causing any serious adverse reactions. The news did not include any reports on the vaccines' efficacy, which must wait for more data. At a news conference, Zheng Zhongwei, head of China ’s COVID-19 vaccine development task force, said China is expected to produce as many as 610 million vaccine doses by the end of this year. More details.... Share this with colleagues: // //
